ライフサイエンスコーパス: leukotriene C

1 of HLMC profoundly increased the release of leukotriene C(4) (>500 times), PGD(2) (>200 times), and

2 tive inhibition by both amphiphiles, such as leukotriene C(4) (K(i(app)), 1.5 microM), glycolithochol

3 Leukotriene B(4) (LTB(4)) and leukotriene C(4) (LTC(4)) act through G protein-coupled

4 gical concentrations of the receptor agonist leukotriene C(4) (LTC(4)) evoke repetitive cytoplasmic C

5 ivate eosinophils and basophils for enhanced leukotriene C(4) (LTC(4)) generation by distinct signali

6 ptors on leukocytes to induce degranulation, leukotriene C(4) (LTC(4)) generation, and chemokine CCL2

7 e signaling cascades leading to secretion of leukotriene C(4) (LTC(4)) is controlled independently of

8 Injection of leukotriene C(4) (LTC(4)) or its nonhydrolyzable form NM

9 inophils to affect their capacity to release leukotriene C(4) (LTC(4)) or their preformed stores of c

10 Both fMLP-induced AA release and leukotriene C(4) (LTC(4)) secretion were inhibited conce

11 Leukotriene C(4) (LTC(4)) synthase conjugates LTA(4) wit

12 glutathione S-transferase and membrane-bound leukotriene C(4) (LTC(4)) synthase.

13 hese double-mutant mice are unable to cleave leukotriene C(4) (LTC(4)) to LTD(4), indicating that thi

14 ration from skin to lymph nodes utilizes the leukotriene C(4) (LTC(4)) transporter multidrug resistan

15 The uptake of 50nM [3H]leukotriene C(4) (LTC(4)) was measured in a 96-well micr

16 logically active glutathione adduct has been leukotriene C(4) (LTC(4)), another eicosanoid that exert

17 n by release of beta-hexosaminidase, PGD(2), leukotriene C(4) (LTC(4)), IL-5, IL-6, IL-13, GM-CSF, an

18 in, verapamil, CSA, and vanadate, but not by leukotriene C(4) (LTC(4)), indicating the involvement of

19 t proinflammatory lipid mediators comprising leukotriene C(4) (LTC(4)), LTD(4), and LTE(4).

20 a major source of the eicosanoids PGD(2) and leukotriene C(4) (LTC(4)), which contribute to allergic

21 achidonic acid (AA) release and secretion of leukotriene C(4) (LTC(4)).

22 levels of the cysteinyl leukotriene (cys-LT) leukotriene C(4) (LTC(4)).

23 2) , tetranor-PGE-M, 8-iso-PGF(2) alpha, and leukotriene C(4) , D(4) , and E(4) , were determined usi

24 Further, GGL-deficient mice show leukotriene C(4) accumulation and significantly more air

25 MRP1-dependent transport of leukotriene C(4) and estradiol-17beta-d-glucuronide into

26 nt transport of the glutathione S-conjugates leukotriene C(4) and S-(2, 4-dinitrophenyl)glutathione a

27 Our data show that the K(m) values for leukotriene C(4) are equivalent for GGT1 and GGT5 at 10.

28 ded in gel-phase EliCell preparations showed leukotriene C(4) generation at the nuclear envelope and

29 nulate and release eosinophil peroxidase and leukotriene C(4) in a dose-dependent manner.

30 D(4) in vivo either in blood when exogenous leukotriene C(4) is administered intravenously or in bro

31 F-alpha, IL-8, PGE(2), leukotriene B(4), and leukotriene C(4) levels were significantly reduced, as w

32 Treg or Tconv cells suppressed IgE-mediated leukotriene C(4) production but enhanced cytokine produc

33 However, arachidonic acid release and leukotriene C(4) production stimulated by zymosan and C.

34 PI3K-Akt cascades, as well as the increased leukotriene C(4) release observed in response to fMLP in

35 AT6(-/-) mice exhibited normal histamine and leukotriene C(4) release, but their cytokine release was

36 rs PD98059 or U0126 inhibited the release of leukotriene C(4) stimulated by fMet-Leu-Phe in IL-5-prim

37 rleukin (IL)-4 upregulates the expression of leukotriene C(4) synthase (LTC(4)S) by human cord blood-

38 lase (sEH) and the glutathione S-transferase leukotriene C(4) synthase (LTC(4)S) each catalyze conver

39 Leukotriene C(4) synthase (LTC(4)S) is responsible for t

40 cally induced the steady-state expression of leukotriene C(4) synthase (LTC(4)S) mRNA within 6 h, and

41 sitized with D. farinae-pulsed BMDCs lacking leukotriene C(4) synthase (LTC(4)S), CysLT(1)R, or both

42 Leukotriene C(4) synthase (LTC(4)S), the terminal 5-lipo

43 ion and challenge protocol with mice lacking leukotriene C(4) synthase (LTC(4)S), the terminal enzyme

44 ely, in a strain with targeted disruption of leukotriene C(4) synthase to prevent cys-LT synthesis.

45 jury was observed in transgenic mice lacking leukotriene C(4) synthase, hemopoietic PGD(2) synthase,

46 ignaling via EP2 inhibits the 5-lipoxygenase/leukotriene C(4) synthase-dependent pathway, the deficie

47 , is primarily responsible for conversion of leukotriene C(4) to leukotriene D(4), the most potent of

48 al for the MRP1-mediated drug resistance and leukotriene C(4) transport activity.

49 sphingosine transporter Abcb1 (Mdr1) and the leukotriene C(4) transporter Abcc1 (Mrp1).

50 ands and CCR8 for emigration to DLN, but the leukotriene C(4) transporter multidrug resistance-relate

51 cretion and production of the lipid mediator leukotriene C(4) were unaffected.

52 nant mCysLT(2)R with a rank order of potency leukotriene C(4)(LTC(4) ) = LTD(4)>>LTE(4).

53 , transports conjugated organic anions (e.g. leukotriene C(4)) and also co-transports certain unmodif

54 re-induced leukotriene (leukotriene B(4) and leukotriene C(4)) production, indicating 5-lipoxygenase

55 (e.g., histamine), lipid metabolites (e.g., leukotriene C(4)), and cytokines (e.g., IL-4/IL-13), whi

56 d Synta-66 reduced the release of histamine, leukotriene C(4), and cytokines (IL-5/-8/-13 and TNFalph

57 Intranasal leukotriene C(4), D(4), and E(4) were administered to na

58 t cell (MC) mediators (histamine, serotonin, leukotriene C(4), prostaglandin D2, and mouse mast cell

59 as the release of the proinflammatory factor leukotriene C(4).

60 e substrate binding pockets of As(GS)(3) and leukotriene C(4).

61 release of eosinophil-derived neurotoxin and leukotriene C(4).

62 nist-induced prostaglandin E(2) (PGE(2)) and leukotriene C(4)/D(4)/E(4) production during lipoprotein

63 kines IL-4, IL-5, IL-13, IL-25, and eotaxin; leukotriene C(4); and total as well as allergen-specific

64 trate direct binding of U46619 and cysteinyl leukotrienes C(4), D(4) and E(4) to the P. papatasi prot